Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.992
Filter
1.
Arch Esp Urol ; 77(4): 368-377, 2024 May.
Article in English | MEDLINE | ID: mdl-38840279

ABSTRACT

PURPOSE: This systematic review and meta-analysis aimed to compare the effectiveness and safety of submucosal injection of onabotulinum toxin A (OnabotA) with intradetrusor injection for overactive bladder syndrome (OAB). METHODS: This systematic review is registered with PROSPERO (CRD42021237964). A licensed librarian surveyed Medline, EMBASE, Scopus, and Google Scholar databases to conduct a comprehensive search. Studies comparing suburothelial and intradetrusor techniques of OnabotA injection for OAB were included, along with clinical and urodynamic variables and complications. The studies were assessed for quality on the basis of Cochrane Collaboration guidelines and evaluated using statistical analysis via a random-effect model and I2 statistic. Data extraction and analysis were conducted using Covidence systematic review platform and Review Manager software. RESULTS: Six studies with 299 patients were included in the systematic review, with four reporting that suburothelial injection of OnabotA was as effective as intradetrusor injection and two reporting intradetrusor injection to be more effective. The meta-analysis found no significant difference between the suburothelial and intradetrusor groups for mean daily catheter or voiding frequency (mean difference: 2.12 [95% confidence interval (CI): -1.61, 5.84]) and the mean number of urgency/urge incontinence episodes (mean difference: 0.08 [95% CI: -1.42, 1.57]). However, a significant heterogeneity was found among the studies. Only the mean volume at first detrusor contraction showed a significant difference, being higher for suburothelial injection (mean difference: 33.39 [95% CI: 0.16, 66.63]). No significant difference was noted for mean compliance, mean bladder capacity, and mean maximum detrusor pressure. Urinary tract infections (UTIs) (p = 0.24) and acute urinary retention (p = 0.92) showed no significant difference between the two groups. The risk of bias varied among the studies. CONCLUSIONS: Suburothelial injection of OnabotA is as effective as intradetrusor injection in improving OAB symptoms, and it has similar complication rates. A higher mean volume of the first detrusor contraction was found in a urodynamic study with suburothelial injection.


Subject(s)
Botulinum Toxins, Type A , Urinary Bladder, Overactive , Botulinum Toxins, Type A/administration & dosage , Humans , Urinary Bladder, Overactive/drug therapy , Adult , Urinary Bladder, Neurogenic/drug therapy , Injections
2.
ScientificWorldJournal ; 2024: 7446251, 2024.
Article in English | MEDLINE | ID: mdl-38854678

ABSTRACT

This paper explores the role of botulinum neurotoxin in aiding fracture recovery through temporary muscle paralysis. Specifically, it investigates the effects of botulinum neurotoxin-induced paralysis of the sternocleidomastoid muscle on clavicle fractures in rats. The research aims to assess safety, effectiveness, and the impact on fracture healing. Healthy male Albino Wistar rats were divided into four groups: clavicle fracture, botulinum neurotoxin injection, both, and control. Surgeries were conducted under anaesthesia, and postoperatively, animals were monitored for 28 days. Euthanasia and radiological assessment followed, examining fracture healing and muscle changes, while tissues were histopathologically evaluated. The modified Lane-Sandhu scoring system was used for the radiographic evaluation of clavicle fractures, and the results varied from complete healing to nonunion. Histopathological examination at 28 days postfracture showed fibrous tissue, mesenchymal cells, and primary callus formation in all groups. Despite varied callus compositions, botulinum neurotoxin administration did not affect clavicle healing, as evidenced by similar scores to the control group. Several studies have explored botulinum neurotoxin applications in fracture recovery. Research suggests its potential to enhance functional recovery in certain types of fractures. Theoretical benefits include managing muscle spasticity, aiding reduction techniques, and preventing nonunion. However, botulinum neurotoxin's transient effect and nonuniversal applications should be considered. The present study found that botulinum toxin had no clear superiority in healing compared to controls, while histological evaluation showed potential adverse effects on muscle tissue. Further research is essential to understand its risk-benefit balance and long-term effects.


Subject(s)
Botulinum Toxins, Type A , Fracture Healing , Fractures, Bone , Rats, Wistar , Animals , Botulinum Toxins, Type A/pharmacology , Botulinum Toxins, Type A/administration & dosage , Rats , Male , Fracture Healing/drug effects , Fractures, Bone/drug therapy , Conservative Treatment/methods , Clavicle/injuries , Clavicle/drug effects , Disease Models, Animal
4.
Tunis Med ; 102(4): 200-204, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38746958

ABSTRACT

INTRODUCTION: Stump hyperhidrosis is a common condition after lower limb amputation. It affects the prosthesis use, and the quality of life of patients. Several case reports tried to prove benefit of using Botulinum toxin in its treatment. AIM: This study was to conduct a larger workforce clinical trial and to demonstrate benefits of botulinum toxin injection in the treatment of stump hyperhidrosis. METHODS: A prospective study was conducted. War amputees who complained of annoying excessive sweating of the stump were included. They received intradermal injection of botulinum toxin A in the residual limb area in contact with prosthetic socket. Abundance of sweating and degree of functional discomfort associated with it were assessed before, after 3 weeks, 6 and 12 months. RESULTS: Seventeen male patients, followed for post-traumatic limb amputation were included in the study. Discomfort and bothersome in relation to Hyperhidrosis did decrease after treatment (p<0,001). Reported satisfaction after 3 weeks was 73,33%. Improvement of prothesis loosening up after 3 weeks was 72,5% [±15,6]. Mean injection-induced pain on the visual analogue scale was 5.17/10 (±1.58). The mean interval after the onset of improvement was 5.13 days [min:3, max:8]. The mean time of improvement was 10.4 months after the injection [min:6, max:12]. No major adverse events were reported following treatment. CONCLUSION: Intradermal injections of botulinum toxin in the symptomatic treatment of stump hyperhidrosis are effective and have few adverse effects. It improves the quality of life of our patients thanks to a better tolerance of the prosthesis.


Subject(s)
Amputation Stumps , Amputees , Botulinum Toxins, Type A , Hyperhidrosis , Humans , Hyperhidrosis/drug therapy , Male , Adult , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/adverse effects , Prospective Studies , Artificial Limbs/adverse effects , Injections, Intradermal , Middle Aged , Warfare , Quality of Life , Young Adult , Treatment Outcome
5.
BMJ Case Rep ; 17(5)2024 May 15.
Article in English | MEDLINE | ID: mdl-38749514

ABSTRACT

Paradoxical masseteric bulging refers to an unexpected occurrence of masseter muscle bulging or protrusion following the administration of botulinum toxin injections, contrary to the anticipated muscle weakening effect. It may occur secondary to toxin failing to diffuse through the entire masseter muscle due to the presence of an inferior tendon structure within the superficial masseter that divides it into a superficial and deep belly. We report a clinical case of paradoxical masseteric bulging in a female in her late 40s who developed this adverse effect within a week of her masseter botulinum neurotoxin type A injections. We also describe the masseter two-site injection technique for the management of this complication.


Subject(s)
Botulinum Toxins, Type A , Masseter Muscle , Neuromuscular Agents , Humans , Female , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/adverse effects , Masseter Muscle/pathology , Masseter Muscle/drug effects , Neuromuscular Agents/administration & dosage , Neuromuscular Agents/adverse effects , Injections, Intramuscular/adverse effects , Middle Aged , Adult
6.
Spinal Cord Ser Cases ; 10(1): 33, 2024 May 04.
Article in English | MEDLINE | ID: mdl-38704389

ABSTRACT

INTRODUCTION: Patients with spinal cord injury (SCI) and incomplete paralysis may experience muscle immobilization due to functional impairment of agonist and antagonist muscles. This can induce spasticity and pain, with the risk of contracture increasing as the period of immobilization increases. This could be aggravated by pain, which interferes with rehabilitation. There is no established treatment for pain and joint contractures caused by acute SCI. Botulinum therapy plays a role in relieving muscle tension. Here, we report a case of acute SCI in which botulinum therapy was administered. CASE PRESENTATION: The patient experienced a C5-cervical SCI due to a road traffic accident, with marked paralysis in the upper and lower limbs below the C5 level. The patient had persistent elbow flexion since the SCI and complained of excruciating pain, making adequate rehabilitation difficult. Botulinum toxin was administered to the biceps and brachialis muscles 15 days after the SCI. After administration, the patient experienced a reduction in pain with relaxation of the elbow flexor muscles, and rehabilitation treatment was resumed. This patient's contracture did not worsen, his pain decreased, and he was able to initiate self-feeding training. DISCUSSION: In this case, occupational and physical therapy was administered with botulinum therapy. Together, they successfully reduced pain. Botulinum therapy provides analgesia and muscle relaxation and may lead to functional recovery, and we believe that treatment can be considered even in the acute phase.


Subject(s)
Spinal Cord Injuries , Upper Extremity , Humans , Spinal Cord Injuries/rehabilitation , Spinal Cord Injuries/complications , Male , Neuromuscular Agents/therapeutic use , Neuromuscular Agents/administration & dosage , Adult , Botulinum Toxins/therapeutic use , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/administration & dosage , Combined Modality Therapy
9.
Arch Dermatol Res ; 316(6): 212, 2024 May 24.
Article in English | MEDLINE | ID: mdl-38787406

ABSTRACT

The use of botulinum toxin for off-label indications has become more prevalent, but the specific benefits in Mohs micrographic surgery (MMS) have not yet been fully elucidated. A systematic review was performed of PubMed, Cochrane, EMBASE, and Scopus databases to identify all articles describing the use of botulinum toxin in MMS. Analysis was subdivided into scar minimization, parotid injury, and pain management. A total of nine articles were included. Scar minimization and treatment of parotid injury were the most reported uses. One case reported the use of botulinum toxin for pain management. Off label uses of botulinum toxin are being explored. Additional research is warranted to determine the efficacy and utility of botulinum toxin in MMS.


Subject(s)
Cicatrix , Mohs Surgery , Off-Label Use , Humans , Cicatrix/drug therapy , Skin Neoplasms/surgery , Skin Neoplasms/drug therapy , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins/administration & dosage , Pain Management/methods , Parotid Gland/surgery
10.
J Craniofac Surg ; 35(4): 1089-1091, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38709042

ABSTRACT

BACKGROUND: This study explores the dynamic changes in plastic surgery practices, focusing on the growth rates across different subcategories, particularly highlighting the trends in the United States. OBJECTIVES: To analyze evolving trends in plastic surgery using statistical methods, providing insights into the changes and growth patterns in various segments over time. MATERIALS AND METHODS: Utilizing data from 2005 to 2019 from the American Society of Plastic Surgeons, the authors, conducted a comprehensive statistical analysis using the SPSS program to investigate trends in plastic surgery procedures. RESULTS: Our analysis revealed no significant differences in year-on-year growth rates between cosmetic and reconstructive surgery. However, in reconstructive surgery subcategories, maxillofacial surgery showed the highest mean growth rate at 11.61%, though this was not statistically significant. In cosmetic minimally invasive procedures, soft tissue filler injections and botulinum toxin A injections experienced notably higher growth trends compared with microdermabrasion. CONCLUSION: The findings suggest that practitioners considering a career in plastic surgery should not focus solely on choosing between reconstructive and cosmetic surgery. Recognizing substantial growth in cosmetic minimally invasive procedures, especially botulinum toxin A injections and fillers, is vital for making informed career decisions.


Subject(s)
Cosmetic Techniques , Minimally Invasive Surgical Procedures , Plastic Surgery Procedures , Surgery, Plastic , Humans , United States , Plastic Surgery Procedures/trends , Cosmetic Techniques/trends , Minimally Invasive Surgical Procedures/trends , Surgery, Plastic/trends , Dermal Fillers/administration & dosage , Botulinum Toxins, Type A/administration & dosage , Practice Patterns, Physicians'/trends , Societies, Medical
12.
In Vivo ; 38(3): 1332-1337, 2024.
Article in English | MEDLINE | ID: mdl-38688605

ABSTRACT

BACKGROUND/AIM: Botulinum toxin intravesical injection therapy (hereafter, botulinum therapy) is approved in Japan for treating urinary urgency, frequency, and urinary incontinence due to refractory overactive bladder or neurogenic bladder. Although botulinum therapy is classified as urinary incontinence surgery, it is minimally invasive, effective, and safe. However, there are few reports on the actual use of botulinum therapy and examination of its effects and side-effects. Herein, we report real-world data on botulinum therapy. PATIENTS AND METHODS: Patients who received botulinum therapy for refractory overactive bladder at the Nara Medical University and affiliated facilities from May 2020 to May 2022 were enrolled. The patient background, treatment efficacy, and safety were retrospectively reviewed. RESULTS: Twenty-three cases of refractory overactive bladder (age: 68.4±14.1 years; 7 males, 16 females; 17 outpatient, 6 hospitalized) were enrolled. Pretreatment, the overactive bladder symptom score (OABSS) was 10.1±2.7, and post-void residual urine volume was 27.1±31.6 ml. Botulinum was administered once, twice, thrice, and four times in 11, eight, three, and one cases, respectively. OABSS decreased to 6.1±3.2 2 weeks after botulinum therapy (p<0.0001), and the effect persisted at 6.6±3.2 after 12 weeks (p<0.0001). Post-void residual urine volume increased to 74.6±79.2 ml after 2 weeks (p=0.0010), but subsequently improved to 33.9±42.0 ml after 12 weeks (p=0.0002). Adverse events included post-void residual urine volume of 200 ml or more in three patients (7.5%) and urinary retention grade 2 in two (5.0%). CONCLUSION: Botulinum therapy is effective and relatively safe for refractory overactive bladders.


Subject(s)
Botulinum Toxins, Type A , Urinary Bladder, Overactive , Humans , Urinary Bladder, Overactive/drug therapy , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/adverse effects , Female , Male , Administration, Intravesical , Aged , Japan , Middle Aged , Treatment Outcome , Aged, 80 and over , Retrospective Studies , East Asian People
13.
Toxins (Basel) ; 16(4)2024 Apr 19.
Article in English | MEDLINE | ID: mdl-38668622

ABSTRACT

Post-stroke spasticity is a common complication that limits the functional performance of patients. Botulinum toxin (BTx) is an effective treatment for spasticity. Numerous researchers have applied extracorporeal shock wave therapy (ESWT) to address post-stroke spasticity, yielding positive clinical outcomes. We aimed to clarify the add-on effects of ESWT on BTx therapy for spasticity in patients with post-stroke. Sixteen eligible patients with upper extremity spasticity after stroke were recruited for this study. They were randomized to either a BTx with focused ESWT treatment group or a BTx alone group. Spasticity, measured using the modified Ashworth score (MAS) and modified Tardieu scale (MTS), showed statistically significant improvements in the elbow and wrist flexor muscles in both BTx + ESWT group and BTx alone groups. However, no significant differences were observed between the two groups with time flow. The BTx + ESWT group showed significantly decreased MAS of the finger flexors at follow-up and increased R1 (MTS) of the finger flexors at 3 weeks after treatment, which was not observed in the BTx alone group. This is the first study to identify the add-on effect of ESWT on BTx injections to improve post-stroke upper limb spasticity.


Subject(s)
Extracorporeal Shockwave Therapy , Muscle Spasticity , Stroke , Upper Extremity , Humans , Muscle Spasticity/drug therapy , Muscle Spasticity/etiology , Muscle Spasticity/therapy , Male , Female , Middle Aged , Stroke/complications , Aged , Treatment Outcome , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/administration & dosage , Neuromuscular Agents/therapeutic use , Neuromuscular Agents/administration & dosage , Combined Modality Therapy , Adult
14.
Ann Plast Surg ; 92(5): 508-513, 2024 May 01.
Article in English | MEDLINE | ID: mdl-38685490

ABSTRACT

BACKGROUND: Botulinum toxin type A is widely used to treat glabellar and forehead wrinkles, but the pain caused by multiple injections often deters patients from receiving long-term treatment. Despite several methods used to alleviate this pain, consistency and effectiveness remain a challenge. Therefore, this study aimed to evaluate the effectiveness and safety of nerve block guided by anatomic landmarks only in reducing pain associated with botulinum toxin type A injections. PATIENTS AND METHODS: Between 2018 and 2022, the study enrolled 90 patients divided into 3 groups: the nerve block group (n = 30), the lidocaine cream group (n = 30), and the control group (n = 30). In the nerve block group, a landmarks-based technique was used to perform the nerve block. The study collected general information and comorbidities, and recorded pain at each point and time spent on preparation and treatment for each patient's forehead and glabellar area on each side. Patient-reported outcomes and complications were followed up at 2, 4, and 12 weeks after the injections. RESULTS: The nerve block group had significantly lower total pain scores in all regions compared to the lidocaine cream and control groups (P < 0.01). There were no significant differences in patient-reported outcomes between the groups at any follow-up point. Additionally, the complication rates related to injection were low and comparable among the 3 groups. CONCLUSIONS: Nerve block guided by anatomic landmarks only is a safe, effective, and consistent approach to reduce pain during botulinum toxin type A treatment for glabellar and forehead lines. This technique may offer advantages over other methods used to alleviate the pain associated with these injections.


Subject(s)
Anatomic Landmarks , Botulinum Toxins, Type A , Forehead , Nerve Block , Skin Aging , Humans , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/therapeutic use , Forehead/innervation , Female , Nerve Block/methods , Middle Aged , Male , Skin Aging/drug effects , Adult , Neuromuscular Agents/administration & dosage , Neuromuscular Agents/therapeutic use , Pain Measurement , Lidocaine/administration & dosage , Lidocaine/therapeutic use , Treatment Outcome , Anesthetics, Local/administration & dosage , Anesthetics, Local/therapeutic use
15.
CNS Drugs ; 38(6): 481-491, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38583127

ABSTRACT

BACKGROUND: Many patients with chronic migraine do not achieve clinically meaningful improvement in their headache frequency with monotherapy. The burden associated with chronic migraine calls for a multifaceted treatment approach targeting multiple aspects of migraine pathophysiology. OBJECTIVE: The aim of this study was to evaluate the effect of concurrent anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) and onabotulinumtoxinA (onabot) treatment on median monthly migraine days (MMD) in patients with chronic migraine, through a retrospective study. METHODS: The electronic medical records of Cleveland Clinic patients either concurrently (dual therapy) or consecutively (monotherapy) treated with anti-CGRP mAbs and onabot between June 2018 and November 2021 were extracted. Only adult patients (≥ 18 years of age) were included in this study. MMDs for 194 concurrently treated (86.6% female and a median [interquartile range] age of 51 [41-61] years) and 229 consecutively treated (88.2% female and median age of 47 [IQR 39-57] years) patients were examined at baseline, after first therapy of either anti-CGRP mAb or onabot, and following dual therapy for 3 consecutive months. The reduction of MMDs for each treatment group were compared. The same approach was utilized to compare consecutive monotherapy at separate times (n = 229) and dual-therapy groups. RESULTS: The initial treatment of the dual-therapy group reduced the median (IQR) MMDs from 30 (30-30) to 15 (12-30) [p < 0.0001]. After initiation of dual therapy, the median MMDs was further decreased from 15 (12-30) to 8 (3-22) [p < 0.0001]. A majority [132/194 (68.0%)] of the dual-therapy patients reported a ≥ 50% reduction in MMD and 90/194 (46.4%) reported a ≥ 75% reduction. For the consecutive monotherapy group, median MMDs changed from a baseline of 30 (25-30) to 15 (8-25) from onabot monotherapy and decreased from 25 (15-30) to 12 (4-25) after anti-CGRP mAb monotherapy. Almost half (113/229 [49.3%] from onabot, and 104/229 [45.4%] from anti-CGRP mAb) of these patients achieved a ≥ 50% reduction in MMDs and a minority (38/229 [16.6%] from onabot, and 45/229 [19.7%] from anti-CGRP mAb) achieved a reduction of ≥ 75%. Additionally, dual therapy showed significant improvement in MMDs compared with monotherapy of either treatment (p < 0.0001). CONCLUSION: Dual therapy of anti-CGRP mAbs and onabot may be more efficacious than monotherapy, possibly due to their synergistic mechanisms of action.


Subject(s)
Botulinum Toxins, Type A , Calcitonin Gene-Related Peptide , Migraine Disorders , Humans , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/pharmacology , Retrospective Studies , Female , Migraine Disorders/drug therapy , Migraine Disorders/immunology , Male , Middle Aged , Adult , Calcitonin Gene-Related Peptide/immunology , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Chronic Disease , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Drug Therapy, Combination , Drug Synergism , Treatment Outcome
16.
Toxins (Basel) ; 16(4)2024 Apr 15.
Article in English | MEDLINE | ID: mdl-38668616

ABSTRACT

Botulinum toxin type A (BONT-A) has shown promise in improving the mood-related symptoms of psychiatric disorders by targeting muscles linked to the expression of negative emotions. We conducted a systematic review of past and ongoing efficacy trials of BONT-A therapy for psychiatric disorders to identify relevant trends in the field and discuss the refinement of therapeutic techniques. A comprehensive search for published clinical trials using BONT-A injections for psychiatric disorders was performed on 4 May 2023 through OVID databases (MEDLINE, Embase, APA PsycINFO). Unpublished clinical trials were searched through the ClinicalTrials.gov and International Clinical Trial Registry Platform public registries. The risk of bias was assessed using the JBI Critical Appraisal tools for use in systematic reviews. We identified 21 studies (17 published, 4 unpublished clinical trials) involving 471 patients. The studies focused on evaluating the efficacy of BONT-A for major depressive, borderline personality, social anxiety, and bipolar disorders. BONT-A was most commonly injected into the glabellar area, with an average dose ranging between 37.75 U and 44.5 U in published studies and between 32.7 U and 41.3 U in unpublished trials. The results indicated significant symptom reductions across all the studied psychiatric conditions, with mild adverse effects. Thus, BONT-A appears to be safe and well-tolerated for psychiatric disorders of negative affectivity. However, despite the clinical focus, there was a noted shortage of biomarker-related assessments. Future studies should focus on pursuing mechanistic explorations of BONT-A effects at the neurobiological level.


Subject(s)
Botulinum Toxins, Type A , Clinical Trials as Topic , Mental Disorders , Humans , Mental Disorders/drug therapy , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/administration & dosage , Treatment Outcome
17.
JACC Clin Electrophysiol ; 10(5): 930-940, 2024 May.
Article in English | MEDLINE | ID: mdl-38661602

ABSTRACT

BACKGROUND: Postoperative atrial fibrillation (POAF) is associated with increased morbidity and mortality. Epicardial injection of botulinum toxin may suppress POAF. OBJECTIVES: This study sought to assess the safety and efficacy of AGN-151607 for the prevention of POAF after cardiac surgery. METHODS: This phase 2, randomized, placebo-controlled trial assessed the safety and efficacy of AGN-151607, 125 U and 250 U vs placebo (1:1:1), for the prevention of POAF after cardiac surgery. Randomization was stratified by age (<65, ≥65 years) and type of surgery (nonvalvular/valve surgery). The primary endpoint was the occurrence of continuous AF ≥30 seconds. RESULTS: Among 312 modified intention-to-treat participants (placebo, n = 102; 125 U, n = 104; and 250 U, n = 106), the mean age was 66.9 ± 6.8 years; 17% were female; and 64% had coronary artery bypass graft (CABG) only, 12% had CABG + valve, and 24% had valve surgery. The primary endpoint occurred in 46.1% of the placebo group, 36.5% of the 125-U group (relative risk [RR] vs placebo: 0.80; 95% CI: 0.58-1.10; P = 0.16), and 47.2% of the 250-U group (RR vs placebo: 1.04; 95% CI: 0.79-1.37; P = 0.78). The primary endpoint was reduced in the 125-U group in those ≥65 years of age (RR: 0.64; 95% CI: 0.43-0.94; P = 0.02) with a greater reduction in CABG-only participants ≥65 years of age (RR: 0.49; 95% CI: 0.27-0.87; P = 0.01). Rehospitalization and rates of adverse events were similar across the 3 groups. CONCLUSIONS: There were no significant differences in the rate of POAF with either dose compared with placebo; however, there was a lower rate of POAF in participants ≥65 years undergoing CABG only and receiving 125 U of AGN-151607. These hypothesis-generating findings require investigation in a larger, adequately powered randomized clinical trial. (Botulinum Toxin Type A [AGN-151607] for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery [NOVA]; NCT03779841); A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A [AGN 151607] Injections into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac Surgery; 2017-004399-68).


Subject(s)
Atrial Fibrillation , Botulinum Toxins, Type A , Postoperative Complications , Humans , Atrial Fibrillation/prevention & control , Female , Male , Aged , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/administration & dosage , Middle Aged , Postoperative Complications/prevention & control , Double-Blind Method , Cardiac Surgical Procedures/adverse effects , Treatment Outcome , Coronary Artery Bypass/adverse effects
18.
Headache ; 64(5): 589-594, 2024 May.
Article in English | MEDLINE | ID: mdl-38533675

ABSTRACT

OBJECTIVES: To report the efficacy of onabotulinumtoxinA (BoNTA) injections in relieving pain in patients with primary trochlear headache (PRTH). METHODS: Examination of medical records for patients diagnosed with PRTH according to the International Classification of Headache Disorders, 3rd edition criteria and treated with BoNTA. Data were collected for variables related to pain relief, duration of effectiveness, and adverse effects. RESULTS: Six patients were included in the study. All had previously undergone standard care interventions, including infiltrations or oral treatments, yet experienced treatment failure or symptom recurrence. All patients received 20 units of BoNTA, administered in the corrugator and procerus muscles. Subsequent to the BoNTA injections, all six patients reported substantial pain relief, with five achieving complete remission of symptoms. The analgesic effect persisted for a duration of 3 months. No adverse events were reported in any of the cases. CONCLUSIONS: Our case series presents the first evidence of the potential of BoNTA as a safe and effective treatment option for PRTH. From a clinical standpoint, having a safer alternative is of paramount significance for patients with limited treatment options, such as those with PRTH. Further research is warranted to validate these findings and explore the long-term efficacy of BoNTA in PRTH management.


Subject(s)
Botulinum Toxins, Type A , Humans , Botulinum Toxins, Type A/administration & dosage , Botulinum Toxins, Type A/pharmacology , Female , Retrospective Studies , Adult , Middle Aged , Male , Neuromuscular Agents/administration & dosage , Neuromuscular Agents/pharmacology , Headache Disorders, Primary/drug therapy , Treatment Outcome , Aged , Acetylcholine Release Inhibitors/administration & dosage , Acetylcholine Release Inhibitors/pharmacology
19.
J Oral Maxillofac Surg ; 82(5): 525-530, 2024 May.
Article in English | MEDLINE | ID: mdl-38438110

ABSTRACT

Botulinum toxin (BTX) injection is a common treatment for bruxism, but there is no literature on potential salivary gland complications. This paper presents a case of acute parotitis in a 60-year-old female following BTX injections to the masseter muscle. This case highlights the possible salivary gland complications after injection of BTX into the masticatory muscles. An electronic search of PubMed and Embase databases was conducted to create a literature review in order to delve into the etiology behind the presented case and suggest potential preventive measures to avoid salivary gland complications. Thirty-one articles are reviewed and discussed. Currently, there is no consensus on the causes of the mentioned complication. However, various factors have been proposed, encompassing anatomical, physiological, biological, and physical aspects. Several methods have been recommended for the safe injection of BTX, which, along with better medical training and knowledge, are warranted to achieve predictable results.


Subject(s)
Masseter Muscle , Parotitis , Humans , Female , Middle Aged , Injections, Intramuscular , Botulinum Toxins, Type A/therapeutic use , Botulinum Toxins, Type A/adverse effects , Botulinum Toxins, Type A/administration & dosage , Postoperative Complications/prevention & control , Neuromuscular Agents/therapeutic use , Neuromuscular Agents/adverse effects , Neuromuscular Agents/administration & dosage , Bruxism
20.
Orthod Craniofac Res ; 27 Suppl 1: 115-121, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38459796

ABSTRACT

INTRODUCTION: Folinic acid and botulinum toxin A have shown promising results in wound healing in different studies. This study aimed to compare the effects of these approaches on wound healing after simulating cleft lip surgery in rats. METHODS: In this experimental animal study, after creating lip defects, 30 rats were randomly divided into three groups and received normal saline (CTL), botulinum toxin A (BOT), and folinic acid (FOL). Biopsy from the skin wounds was performed after 14- and 28-days. These samples were stained with haematoxylin and eosin and Masson trichrome staining. Finally, each pathological parameter of wound healing was rated in this study. RESULTS: While the inflammatory response was not different among the study groups, fibroblast proliferation and collagen deposition were significantly higher in FOL group compared to BOT group. Moreover, both BOT and FOL facilitated epithelial healing and 14-day angiogenesis as compared with normal saline. CONCLUSIONS: Improved wound healing was observed using both botulinum toxin A and folinic acid in rat animal models. However, the application of botulinum toxin A caused less fibroblast proliferation and collagen deposition which can potentially lead to less scar formation, which can be particularly important in the aesthetic zone.


Subject(s)
Botulinum Toxins, Type A , Cleft Lip , Wound Healing , Animals , Botulinum Toxins, Type A/pharmacology , Botulinum Toxins, Type A/administration & dosage , Wound Healing/drug effects , Rats , Cleft Lip/surgery , Fibroblasts/drug effects , Collagen , Male , Rats, Wistar , Disease Models, Animal , Cell Proliferation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...